PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för macitentan. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

24 hits

Bibliografisk träff 2014-03-01

Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.

Sidharta PN, Lindegger N, Ulč I, Dingemanse J.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/jcph.193

Bibliografisk träff 2014-01-01

Macitentan: first global approval.

Patel T, McKeage K.

Drugs · journal article · DOI 10.1007/s40265-013-0156-6

Bibliografisk träff 2013-12-01

An update on medical therapy for pulmonary arterial hypertension.

Wu Y, O'Callaghan DS, Humbert M.

Curr Hypertens Rep · review; journal article · DOI 10.1007/s11906-013-0394-8

Bibliografisk träff 2013-12-01

Macitentan approved by FDA to delay progression of PAH.

Thompson CA.

Am J Health Syst Pharm · news · DOI 10.2146/news130076

Bibliografisk träff 2013-11-22

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.

Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H.

Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2014.859674

Bibliografisk träff 2013-09-04

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.

Sidharta PN, van Giersbergen PL, Dingemanse J.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/jcph.152

Bibliografisk träff 2013-09-01

Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?

Seferian A, Simonneau G.

Eur Respir Rev · review-article; review; journal article · DOI 10.1183/09059180.00001713

Bibliografisk träff 2013-08-01

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.

Atsmon J, Dingemanse J, Shaikevich D, Volokhov I, Sidharta PN.

Clin Pharmacokinet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s40262-013-0063-8

Bibliografisk träff 2013-08-01

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators.

N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1213917

Bibliografisk träff 2013-06-26

Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.

Bruderer S, Marjason J, Sidharta PN, Dingemanse J.

Pharmacology · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1159/000351704

Bibliografisk träff 2013-05-16

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.

Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J, MUSIC Study Group.

Eur Respir J · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1183/09031936.00104612

Bibliografisk träff 2013-04-01

Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings.

Corallo C, Pecetti G, Iglarz M, Volpi N, Franci D, Montella A, D' Onofrio F, Nuti R, Giordano N.

J Biol Regul Homeost Agents · research support, non-u.s. gov't; journal article

Bibliografisk träff 2013-01-23

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.

Weiss J, Theile D, Rüppell MA, Speck T, Spalwisz A, Haefeli WE.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2013.01.010

Bibliografisk träff 2012-12-01

Pathways in pulmonary arterial hypertension: the future is here.

Sitbon O, Morrell N.

Eur Respir Rev · review-article; review; journal article · DOI 10.1183/09059180.00004812

Bibliografisk träff 2012-11-28

Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells.

Coffman L, Mooney C, Lim J, Bai S, Silva I, Gong Y, Yang K, Buckanovich RJ.

Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.4161/cbt.22959

Bibliografisk träff 2012-10-15

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0047662

Bibliografisk träff 2012-10-12

Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.

Yao A.

J Cardiol · review; journal article · DOI 10.1016/j.jjcc.2012.08.009

Bibliografisk träff 2012-08-16

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T.

J Med Chem · journal article · DOI 10.1021/jm3009103

Bibliografisk träff 2012-04-13

Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.

Sen S, Chen S, Feng B, Iglarz M, Chakrabarti S.

Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.lfs.2012.03.032

Bibliografisk träff 2012-03-30

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans.

Bruderer S, Hopfgartner G, Seiberling M, Wank J, Sidharta PN, Treiber A, Dingemanse J.

Xenobiotica · clinical trial, phase i; journal article · DOI 10.3109/00498254.2012.664665

Bibliografisk träff 2012-02-06

Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.

Liang F, Yang S, Yao L, Belardinelli L, Shryock J.

Hypertension · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1161/hypertensionaha.111.182261

Bibliografisk träff 2012-02-01

Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Kim SJ, Kim JS, Kim SW, Yun SJ, He J, Brantley E, Fan D, Strickner P, Lehembre F, Regenass U, Fidler IJ.

Transl Oncol · research-article; journal article · DOI 10.1593/tlo.11286

Bibliografisk träff 2011-12-22

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

Bruderer S, Aänismaa P, Homery MC, Häusler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J.

AAPS J · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1208/s12248-011-9316-3

Bibliografisk träff 2011-02-01

Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, Maya M, Zhang F, Wu Q, Lehembre F, Regenass U, Fidler IJ.

Neoplasia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1593/neo.10806